Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapy with monoclonal antibodies. II. The contribution of Fc gamma receptor binding and the influence of C(H)1 and C(H)3 domains on in vivo effector function.

Journal of immunology (Baltimore, Md. : 1950) - 15 Oct 1998

Isaacs J D, Greenwood J, Waldmann H

Abstract excerpt

An in vivo model is used to define Fc motifs engaged by mAbs to deplete target cells. Human IgG1 and human IgG4 were very potent, and mutations within a motif critical for Fc gammaR binding (glutamate 233 to proline, leucine/phenylalanine 234 to valine, and leucine 235 to alanine) completely prev...

Topics

Amino Acid Sequence
Animals
Antibodies, Monoclonal
Binding Sites
Humans
Immunoglobulin G
Mice
Mice, Inbred CBA
Molecular Sequence Data
Mutation
Protein Engineering
Rats

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Receptors, IgG

Structure-Activity Relationship

Source

Identifiers

PMID: 9780151

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026. Prepared record publication-9780151-2026-08-30.1. Manifest publication-graph-cohort-2026-08-30.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapy with monoclonal antibodies. II. The contribution of Fc gamma receptor binding and the influence of C(H)1 and C(H)3 domains on in vivo effector function.PMID 9780151Read ↗

Therapy with Monoclonal Antibodies. II. The Contribution of Fcγ Receptor Binding and the Influence of CH1 and CH3 Domains on In Vivo Effector FunctionSemantic proximity Read ↗

Antibody therapeutics:Semantic proximity Read ↗

Isotype selection for antibody-based cancer therapySemantic proximity Read ↗

Manipulating T cell-mediated pathology: Targets and functions of monoclonal antibody immunotherapySemantic proximity Read ↗

Optimizing therapeutic antibody function: progress with Fc domain engineering.Semantic proximity Read ↗

Fc-Receptor Interactions Regulate Both Cytotoxic and Immunomodulatory Therapeutic Antibody Effector FunctionsSemantic proximity Read ↗

Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-LifeSemantic proximity Read ↗

Differential binding to human FcgammaRIIa and FcgammaRIIb receptors by human IgG wildtype and mutant antibodies.Semantic proximity Read ↗

Asymmetrical Fc engineering greatly enhances antibody-dependent cellular cytotoxicity (ADCC) effector function and stability of the modified antibodies.Semantic proximity Read ↗

Mutation of the TGN1412 anti-CD28 monoclonal antibody lower hinge confers specific FcγRIIb binding and retention of super-agonist activity.Semantic proximity Read ↗

A genetically engineered human IgG mutant with enhanced cytolytic activitySemantic proximity Read ↗

Highly reduced binding to high and low affinity mouse Fc gamma receptors by L234A/L235A and N297A Fc mutations engineered into mouse IgG2a.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.